Oova, Inc. Announces Series A $10.3M and Launches New Oova Membership Model to Empower Women on their Reproductive Journeys
With the capital led by Spero Ventures, Oova meets evolving needs of women's fertility and looks to expand to more areas of women's health.
NEW YORK, June 13, 2023 /PRNewswire-PRWeb/ -- Oova, Inc., a trailblazer in women's health and fertility solutions, is proud to announce its Series A raise of $10.3M, and introduce the new Oova Membership model, designed to provide unparalleled support and empowerment to women as they navigate fertility while trying to conceive. Unlike traditional one-time purchases or subscription-to-refill kits, the Oova Membership offers a comprehensive, ongoing solution for women's reproductive health.
Oova, Inc founder and CEO, Amy Divaraniya, Ph.D., is an expert in biomedical sciences with a focus on genetics. Her personal struggles to conceive due to an irregular menstrual cycle emphasized the lack of resources women have to access instrumental information about their own bodies, leading Divaraniya to the development of Oova's revolutionary technology. Oova is the only test on the market that quantitatively measures luteinizing hormone (LH) and progesterone (PdG) in real time, providing women with daily insights and actionable advice to optimize their chances of conception. It is FDA registered and the only product that allows its users to sync and share results with their doctor in real time. This innovative approach sets Oova apart, empowering women and their doctors with the knowledge they need to make informed decisions about their reproductive health. The Oova Kit launched in 2021 and has already trained its model on over 10,000 cycles monitored through the platform.
This round of funding brought on renowned investors across various industries and executive level expertise. It is led by Spero Ventures, a firm committed to companies with a positive mission, who are creating new markets and solutions for their customers.
"Oova has revolutionized the way we understand our hormonal health," said Sara Eshelman, partner at Spero Ventures. "By making clinical-grade hormone monitoring convenient and cost-effective for daily use, Oova is empowering its users to understand their cycles, improve fertility outcomes, and manage their symptoms. Simultaneously, Oova offers intricate datasets that provide patients and clinicians an unprecedented objective understanding of how hormones affect our health and well-being. We are honored to be part of the team's mission to bring these capabilities to women, and to clinical care as a whole."
Spero Ventures is joined by other strategic firms including US Fertility, Virgin Group, Jefferson Health, Connecticut Innovations, Special Situations Life Sciences Fund, Samsung Next, Hannah Bronfman, and Sara Blakely, the acclaimed businesswoman and founder of Spanx.
"The US Fertility Innovation Fund is proud to partner with and invest in companies with the potential to transform the reproductive space. Oova is poised to do so by providing a more convenient and cost-effective way to measure reproductive hormones at home, "stated Dr. Eduardo Hariton, Managing Director of US Fertility Innovation Fund. "Their assays have been rigorously validated and provide accurate results in minutes, allowing them to meet the unique needs of both patients and providers without some of the hurdles of venipuncture."
Understanding the evolving needs of women on their fertility journeys, Oova, Inc. is proud to launch the Oova Membership to address these needs holistically. Priced at $99 per month, the membership includes The Oova Kit ($159 value) and offers an array of features for women at every step of their fertility journey, including personalized support from Oova's network of professionals.
Key features of the Oova Membership include:
Comprehensive Support: The membership grants access to the Oova Provider network, consisting of experienced healthcare professionals and hormone experts.
Personalized Guidance: Women receive tailored recommendations from hormone experts through consultations.
Community Connection: The Oova Membership fosters a vibrant and supportive community of like-minded women who are on similar journeys to parenthood. By engaging with this community, members can share their experiences, seek support, and forge valuable connections, creating a sense of camaraderie throughout their fertility journeys.
"We recognize that women seeking to start or expand their families desire more than just a test or a tool—they want a comprehensive solution," said Divaraniya. "With the introduction of the Oova Membership, we are excited to provide women with a plan for the next steps in their journey to parenthood. By combining expert guidance, personalized recommendations, and a supportive community, we aim to empower women and ensure they have the tools they need to make informed decisions about their reproductive health."
The launch of the Oova Membership reinforces Oova, Inc.'s commitment to revolutionizing women's health and fertility solutions while being a beacon to help them navigate through each stage of their unique journey. Steadfast in their commitment to being the leading resource for women at the forefront of the femtech industry, the Oova team will continue to introduce access to new products and technology on their mission to address each phase of womanhood; from the beginning of menstruation, on the path to parenthood, and through menopause. To learn more about the Oova Membership and how it can support women on their fertility journeys, please visit oova.life.
For all media inquires, please contact Sara Spiegel at [email protected]
For general inquiries, please contact [email protected]
About Oova, Inc.:
Oova is the fertility translator that fully illuminates a woman's fertility, giving her and her care team the clearest steps to conception. Founded by doctors and backed by Mount Sinai Hospital, Oova has created a consumer-first, data-driven experience valuable to patients and healthcare providers. Oova's at-home urine test measures luteinizing hormone and progesterone to immediately inform a woman of her most fertile days and confirm ovulation. By delivering advanced personalized analytics and real-time action plans with every hormone reading, Oova is transforming the fertility care experience. Oova has partnered with the leading fertility and women's health practices in the United States. To learn more, visit Oova's website.
Media Contact
Sara Spiegel, Oova, 937.478.9235, sara@withsarapr.com
SOURCE Oova
Share this article